Sponsor Deadline
Posted: 4/18/2022

Congressionally Directed Medical Research Programs -- Joint Program Committee 6 Combat Casualty Care Research Program -- Battlefield Resuscitation for Immediate Stabilization of Combat Casualties Award

The intent of this Program Announcement is to support the early development of high-impact materiel products and new ways, methods, or modifications to existing trauma practice (i.e., knowledge products3 ) for future multi-domain operations (MDO) where evacuation capabilities may be significantly delayed or unavailable. Projects should consider the varied expertise levels of the medical providers and the possible diverse environmental conditions. A focus is on enhancing capabilities at the point of greatest need, including life-saving interventions to be rendered immediately post-injury, during periods of prolonged care in-theater. Medical materiel solutions are encouraged to include characteristics relevant to military use in austere, combat environments. Characteristics and concepts to consider include but are not limited to:

• Low-weight and low-cube: Compared to existing materiel products, the product is a smaller size and weight to aid in portability and storage.

• Low-power, longer shelf life: The product has reduced power usage requirements and longer shelf life than currently available products.

• Modularity and interoperability: The materiel product is compatible with and easily added to existing technologies, equipment, or platforms being used by the military.

• Ruggedization: The materiel product is able to withstand harsh and varied environments such as extreme temperature fluctuations, vibration, and high altitude while maintaining operability and stability.

• Low-complexity, decision-supported, closed or semi-closed loop feedback or automation: The product is simple to operate, provides decision support to user, and can be partially or fully autonomous. The product can be used by various levels of medical providers with minimal training.

• Affordability: The materiel and knowledge products would result in cost-savings over what is currently available and considers the costs of maintaining and sustaining the product.



• Pre-Application Deadline: Jan. 21, 2021
• Invitation to Submit an Application: Feb. 2021
• Application Submission Deadline: April 7, 2021

Areas of Interest

Hemorrhage is the leading cause of preventable deaths among combat casualties occurring before a medical treatment facility is reached. The Battlefield Resuscitation for Immediate Stabilization of Combat Casualties (BRISCC) portfolio seeks to provide materiel and knowledge solutions to enable the immediate stabilization at the point of injury. Current strategic objectives are to provide: (1) technologies to control bleeding in the pre-hospital environment, (2) safer, more effective, and more logistically supportable blood products, and (3) technologies and knowledge sets for improved damage control resuscitation.

The JPC-6/CCCRP has identified the following Focus Areas for funding under the FY21 DMRDP JPC-6/CCCRP BRISCC Award. To meet the intent of the award mechanism, applications MUST specifically address at least one of the BRISCC Award Focus Areas. The BRISCC Award Focus Areas are:

• Novel and/or advanced blood products or volume expanders with oxygen-carrying capacity that offer physiological, logistical, or cost advantages over current products. Note: Research proposing hemoglobin-based oxygen carrier (HBOC) must demonstrate how nitric oxidescavenging will be addressed.

• Tools and techniques to optimize and sustain (more than 12 hours) resuscitation for hemorrhagic shock injuries with an intent to support large-scale multi-domain operations (MDO1 ) and mass casualty-like scenarios.

• Innovative and novel technologies that can stop life-threatening bleeding in the torso region of patients who are delayed in receiving definitive surgical care.

• Innovative and novel devices, drugs, therapies, and clinical practice techniques to treat combat-related and trauma-induced injuries in the pre-hospital setting

Eligibility Requirements

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.

Amount Description

Research Scope: The FY21 DMRDP JPC-6/CCCRP BRISCC Award is structured with three different funding levels based on the scope of the research proposed. It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the proposed research project. The Government reserves the right to fund an application at a lower funding level.

• Funding Level 1: Innovative, high-risk/high-reward research that is in the early stages of idea development or is an untested theory that addresses an important problem. Preliminary data are not required.

• Funding Level 2: Preclinical and clinical research that is supported by substantial preliminary or published data. Clinical trials are not allowed under this funding opportunity.

• Funding Level 3: Advanced preclinical and clinical research supported by substantial preliminary or published data that require additional financial resources due to maturity of the research proposed. Clinical trials are not allowed under this funding opportunity.

The anticipated total costs budgeted for the entire period of performance for an FY21 DMRDP BRISCC Award Funding Level 1 will not exceed $800,000. The anticipated total costs budgeted for the entire period of performance for an FY21 DMRDP BRISCC Award Funding Level 2 will not exceed $1.25 million (M). The anticipated total costs budgeted for the entire period of performance for an FY21 DMRDP BRISCC Award Funding Level 3 will not exceed $2.0M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.